| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1185/030079905X43686 |
| P698 | PubMed publication ID | 15974563 |
| P2093 | author name string | Chang Yu | |
| Sean P Curtis | |||
| Alise S Reicin | |||
| James A Bolognese | |||
| Douglas J Watson | |||
| Dena R Ramey | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 715-722 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Current Medical Research and Opinion | Q5195063 |
| P1476 | title | The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis | |
| P478 | volume | 21 |
| Q28472098 | A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example |
| Q28218005 | An economic model of long-term use of celecoxib in patients with osteoarthritis |
| Q56113559 | Analgesics and Antipyretics |
| Q37862577 | Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials |
| Q41998132 | Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q43133532 | Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis |
| Q35098611 | Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway |
| Q38035095 | Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs |
| Q28219220 | Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk |
| Q92577857 | Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users |
| Q39320502 | Efficacy and safety of etoricoxib in the treatment of osteoarthritis |
| Q45863072 | Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia A. |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q35954438 | Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis |
| Q35849418 | Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy |
| Q49160612 | Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association |
| Q37085249 | Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists |
| Q48615633 | Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. |
| Q57221140 | Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib |
| Q57169425 | Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity |
| Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
| Q40976343 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal |
| Q36600810 | Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. |
| Q41523582 | Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study |
| Q39173912 | The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty |
Search more.